Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases.

Authors

Joanne Kurtzberg, Duke University Medical CenterFollow
Susan Buntz, Duke University Medical Center
Tracy Gentry, Duke University Medical Center
Pamela Noeldner, Duke University Medical Center
April Ozamiz, Duke University Medical Center
Benjamin Rusche, Duke University Medical Center
Robert W. Storms, Duke University Medical Center
Amy Wollish, Duke University Medical Center
David A Wenger, Thomas Jefferson UniversityFollow
Andrew E. Balber, Duke University Medical Center

Document Type

Article

Publication Date

6-1-2015

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Cytotherapy

Volume 17, Issue 6, June 2015, Pages 803-815.

The published version is available at DOI: 10.1016/j.jcyt.2015.02.006. Copyright © Elsevier

Abstract

BACKGROUND AIMS: Cord blood (CB) transplantation slows neurodegeneration during certain inherited metabolic diseases. However, the number of donor cells in the brain of patients does not appear to be sufficient to provide benefit until several months after transplant. We developed the cell product DUOC-01 to provide therapeutic effects in the early post-transplant period.

METHODS: DUOC-01 cultures initiated from banked CB units were characterized by use of time-lapse photomicroscopy during the 21-day manufacturing process. Antigen expression was measured by means of flow cytometry and immunocytochemistry; transcripts for cytokines and enzymes by quantitative real-time polymerase chain reaction; activities of lysosomal enzymes by direct biochemical analysis; alloreactivity of DUOC-01 and of peripheral blood (PB) mononuclear cells (MNC) to DUOC-01 by mixed lymphocyte culture methods; and cytokine secretion by Bioplex assays.

RESULTS: DUOC-01 cultures contained highly active, attached, motile, slowly proliferating cells that expressed common (cluster of differentiation [CD]11b, CD14 and Iba1), M1 type (CD16, inducible nitric oxide synthase), and M2-type (CD163, CD206) macrophage or microglia markers. Activities of 11 disease-relevant lysosomal enzymes in DUOC-01 products were similar to those of normal PB cells. All DUOC-01 products secreted interleukin (IL)-6 and IL-10. Accumulation of transforming growth factor-β, IL-1β, interferon-γ and TNF-α in supernatants was variable. IL-12, IL-2, IL-4, IL-5 and IL-13 were not detected at significant concentrations. Galactocerebrosidase, transforming growth factor-β and IL-10 transcripts were specifically enriched in DUOC-01 relative to CB cells. PB MNCs proliferated and released cytokines in response to DUOC-01. DUOC-01 did not proliferate in response to mismatched MNC.

CONCLUSIONS: DUOC-01 has potential as an adjunctive cell therapy to myeloablative CB transplant for treatment of inherited metabolic diseases.

Recommended Citation

Kurtzberg, Joanne; Buntz, Susan; Gentry, Tracy; Noeldner, Pamela; Ozamiz, April; Rusche, Benjamin; Storms, Robert W.; Wollish, Amy; Wenger, David A; and Balber, Andrew E., "Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases." (2015). Department of Neurology Faculty Papers. Paper 112.
https://jdc.jefferson.edu/neurologyfp/112

PubMed ID

25770677